Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia

World Journal of Gastroenterology

Volumn 19, Issue 32, 2013, Pages 5286-5294

  Aissi, Sana ^a,b   Buisine, Marie Pierre ^b,c,d   Zerimech, Farid ^c   Kourda, Nadia ^e   Moussa, Amel ^e   Manai, Mohamed ^a   Porchet, Nicole ^b,c,d  

^a UNIVERSITY OF TUNIS   (Tunisia)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

^e CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

DNA mismatch repair; KRAS; Mucin 5AC; TP53

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MUCIN 5AC; PROTEIN MLH1; PROTEIN P53; BETA CATENIN; BRAF PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; MUC5AC PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; COLORECTAL CANCER; COMPARATIVE STUDY; DNA METHYLATION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC PARAMETERS; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MISSENSE MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; CHEMISTRY; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PEDIGREE; PROMOTER REGION; RETROSPECTIVE STUDY; RISK FACTOR; TUNISIA; VERY ELDERLY; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA MISMATCH REPAIR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUCIN 5AC; MUTATION; NUCLEAR PROTEINS; PEDIGREE; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA; YOUNG ADULT;

EID: 84882947593     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i32.5286     Document Type: Article

References (37)

1. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627 [PMID: 9121588 DOI: 10.1038/386623a0]
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532 [PMID: 2841597 DOI: 10.1056/ NEJM198809013190901]
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]
4. Peltomäki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 735-740 [PMID: 11257106 DOI: 10.1093/hmg/10.7.735]
5. Johnson V, Volikos E, Halford SE, Eftekhar Sadat ET, Popat S, Talbot I, Truninger K, Martin J, Jass J, Houlston R, Atkin W, Tomlinson IP, Silver AR. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 2005; 54: 264-267 [PMID: 15647192 DOI: 10.1136/gut.2004.048132]
6. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13: 343-346 [PMID: 8673134 DOI: 10.1038/ng0796-343]
7. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002; 62: 2447-2454 [PMID: 11980631]
8. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-2311 [PMID: 15294875 DOI: 10.1093/hmg/ddh238]
9. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686 [PMID; 10411935 DOI: 10.1073/pnas.96.15.8681]
10. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-845 [PMID: 16143123 DOI: 10.1053/j.gastro.2005.06.020]
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954 [PMID: 12068308 DOI: 10.1038/nature00766]
12. Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Møller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-362 [PMID: 17327285 DOI: 10.1136/jmg.2007.048991]
13. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, Smith LD, Jennings K, Grubb G, Royce SG, Walsh MD, Barker MA, Young JP, Jass JR, St John DJ, Macrae FA, Giles GG, Hopper JL. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005; 23: 6524-6532 [PMID; 16116158 DOI: 10.1200/JCO.2005.04.671]
14. Moussa SA, Moussa A, Kourda N, Mezlini A, Abdelli N, Zerimech F, Najjar T, Jilani SB, Porchet N, Ayed FB, Manai M, Buisine MP. Lynch syndrome in Tunisia: first description of clinical features and germline mutations. Int J Colorectal Dis 2011; 26: 455-467 [PMID: 21311894 DOI: 10.1007/ s00384-010-1129-9]
15. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 2004; 4: 153-158 [PMID: 14964310 DOI: 10.1038/nrc1278]
16. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002; 123: 1804-1811 [PMID: 12454837 DOI: 10.1053/ gast.2002.37070]
17. Buisine MP, Devisme L, Savidge TC, Gespach C, Gosselin B, Porchet N, Aubert JP. Mucin gene expression in human embryonic and fetal intestine. Gut 1998; 43: 519-524 [PMID: 9824580]
18. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61: 900-902 [PMID: 11221878]
19. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-1456 [PMID: 10348829 DOI: 10.1186/1897-4287-6-2-99]
20. Katballe N, Christensen M, Wikman FP, Ørntoft TF, Laurberg S. Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 2002; 50: 43-51 [PMID: 11772966 DOI: 10.1136/gut.50.1.43]
21. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, Chadwick RB, Kääriäinen H, Eskelinen M, Järvinen H, Mecklin JP, de la Chapelle A. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-1487 [PMID: 9593786]
22. Iino H, Simms L, Young J, Arnold J, Winship IM, Webb SI, Furlong KL, Leggett B, Jass JR. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut 2000; 47: 37-42 [PMID: 10861262 DOI: 10.1136/gut.47.1.37]
23. Biemer-Hüttmann AE, Walsh MD, McGuckin MA, Simms LA, Young J, Leggett BA, Jass JR. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res 2000; 6: 1909-1916 [PMID: 10815915]
24. Aissi-Ben Moussa S, Moussa A, Lovecchio T, Kourda N, Najjar T, Ben Jilani S, El Gaaied A, Porchet N, Manai M, Buisine MP. Identification and characterization of a novel MLH1 genomic rearrangement as the cause of HNPCC in a Tunisian family: evidence for a homologous Alu-mediated recombination. Fam Cancer 2009; 8: 119-126 [PMID: 18792805 DOI: 10.1007/s10689-008-9215-7]
25. Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, Saragoni L, Amadori D. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 2005; 204: 484-488 [PMID: 15702478 DOI: 10.1002/jcp.20310]
26. de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, Porte RJ, Slooff MJ, van Goor H, van den Berg A. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 2005; 11: 4067-4073 [PMID: 15930341 DOI: 10.1158/1078-0432.CCR-04-2389]
27. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878 [PMID: 8069852]
28. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 9433-9438 [PMID: 12093899 DOI: 10.1073/pnas.122612899]
29. Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, Robertson MA, Nichols MF, Gruenthal KM, Lynch BJ, Leppert MF, Slattery ML. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 2001; 158: 1517-1524 [PMID: 11290569 DOI: 10.1016/S0002-9440(10)64102-8]
30. Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998; 4: 203-210 [PMID: 9516972]
31. Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, Jungling B, Zeuzem S, Raedle J. BRAF mutations in colorectal carcinoma suggest two entities of microsatelliteunstable tumors. Cancer 2005; 104: 952-961 [PMID: 16015629 DOI: 10.1002/cncr.21266]
32. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130 [PMID: 17204026 DOI: 10.1111/ j.1365-2559.2006.02549.x]
33. Fink BR, Cullen BF. Anesthetic pollution: What is happening to us? Anesthesiology 1976; 45: 79-83 [PMID: 937755]
34. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R, Searle J, McKeone D, Fraser L, Purdie DR, Podger K, Price R, Buttenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107-2116 [PMID: 11733361 DOI: 10.1016/ S0002-9440(10)63062-3]
35. Hill J, Walsh S, Evans DG. Screening of patients at high risk of colorectal cancer. Colorectal Dis 2001; 3: 308-311 [PMID; 12790951 DOI: 10.1046/j.1463-1318.2001.00254.x]
36. Vasen HFA, Morreau H. Familial and hereditary colorectal colorectal cancer with emphasis on the hereditary non-polyposis colorectal cancer syndrome. Curr Diagn Pathol 2002; 8: 241-248 [DOI: 10.1054/cdip.2002.0124]
37. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]